The application of fibroblast activation protein(FAP)in cancer-associated fibroblast(CAF)has garnered widespread attention in nuclear medicine.FAP is highly expressed in most cancer tissues and rarely expressed in healthy tissues.Therefore,radionuclide probes targeting FAP have significant diagnostic and therapeutic potential.Compared to 18F-FDG,widely used in clinical practice,FAP-targeted tracers exhibit superior target-to-background ratio(tumor-to-background ratio)across various indications.Unlike 18F-FDG,the clinical use of FAP-targeted tracers does not require complex preparations like dietary restrictions for patients and offers the possibility of radioligand therapy(RLT).While radiolabeled antibodies have been studied clinically since the 1990s,the introduction and clinical application of FAPI tracers in 2018 marked a breakthrough event in the development of FAP-targeted probes within nuclear medicine.Since then,the development and application of targeted FAP tracers have become a hot topic among pharmaceutical companies as well as within the radiopharmaceutical and nuclear medicine communities.This article reviewed the current status and research progress of FAP-targeted radiopharmaceuticals.
关键词
成纤维细胞活化蛋白抑制剂/正电子发射体层成像/计算机体层成像探针/放射性探针/核医学显像
Key words
Fibroblast activation protein inhibitor/Positron emission tomography/computed tomography probes/Radioactive tracer/Nuclear imaging
维普
万方数据